Nuvation Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
9analysts covering
FY Revenue (est.)
$201.1Mnext fiscal year
FY EPS (est.)
-$0.29next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| FDA Target Action Date for IBTROZI sNDA (Updated Data) | 4 Jan 2027 |
Monitoring Framework
Key Performance Indicators
IBTROZI (taletrectinib) Net U.S. Product Revenue Quarterly18.5M
New Patient Starts on IBTROZI Quarterly200.0
Proportion of TKI-Naïve Patients in New Starts Quarterly0.5
Cash, Cash Equivalents, and Marketable Securities Quarterly533.7M
Watch Items
- Safusidenib Phase 3 SIGMA Trial Enrollment and Data ReadoutTrigger: Topline data readout expected in 2027-2028Action: Monitor clinical trial progress and potential accelerated approval filings based on Objective Response Rate (ORR).
- IBTROZI European Union Regulatory ApprovalTrigger: EMA validation of Marketing Authorisation Application (MAA) in March 2026Action: Track regulatory milestones to trigger the expected ~$30 million milestone payment from partner Eisai upon EU approval.
- Competitive Landscape in ROS1+ NSCLC MarketTrigger: FDA PDUFA action date for Nuvalent's zidesamtinib on September 18, 2026Action: Assess market share dynamics and commercial positioning of IBTROZI against newly entering next-generation ROS1 inhibitors.
Research as of 20 Jun 2026